SiNtx Technologies Inc (SINT)

[boston745]

Before i get into Zimmer and Sintx, and not that i actually said Sintx would be acquired for $1+b, do you think Sintx IP could be worth north of a B based on addressable market size and several of its known/possible partner companies? It is worth over $230m based on comparable company and its material and its used $270m developing the tech. Public companies are generally worth more than their private counterparts and the ortho market has grown substantially since 2003. I would like to know what product is being worked on that Si3n4 can be used for Cancer treatments? Thats just 1 market that Si3n4 can play in that Implex Hydrocel couldnt.

List of Markets Sintx can participate in and products in development:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174489883

========================================

I didnt say conclusions were facts. The facts are someone posted Zimmer intends to acquire Sintx, then Amedica, for its tech and this was posted 3 years before Sintx went public so it was not an attempt to pump SINT/AMDA. Furthermore, mentions of Zimmer within Sintx IPO paperwork were removed indicating someone didnt want it widely known Sonny & previous chairman had ties to Zimmer. Since that time Zimmers actions have been consistent with this statement including being a strategic partner with Sintx testing its femoral head as evidence by the following verifiable evidence and hiring of a Si3N4 expert in Dr Lal.

AnonymousMay 24, 2011 at 3:42 PM
Zimmer is looking at purchasing Amedica flat out for their techology to bolster sales in spine through licensing and to purchase the next generation of hip and knee implants. You heard it here on TSB.

Proof Zimmer Biomet is one of Sintx strategic partners:

Sintx 2016 10k

Together with a strategic partner, we have initiated biomechanical testing of our solid silicon nitride femoral heads. The results of this test will be released in 2017

This quote indicates the results of testing of their femoral head with a strategic partner will be released in 2017.
Those results were released testing Sintx Femoral head against Biomet's E1 liners. Thus Zimmer Biomet, or any of its subsidiaries, is Sintx strategic partner in this testing.

Amedica and Zimmer-Biomet (Tokyo Office) provided the femoral heads and acetabular liners; however, neither company actively sponsored the research

These are risk-averse companies that look to smaller companies like us to develop an idea, uh, and, uh, de-risk it, so to speak, and then buy that technology.

Dr Saurabh Lal, PHD (Si3N4 coatings expert)
Dr. Lal has never been directly connected to Sintx that im aware of. Hes included in this list because of his extensive Si3N4 work for European Unions Life Long Joints program for which Sintx has been a partner in. He serves as a Principle Engineer at Zimmer Biomet in Swindon, UK as part of its anti-infection coatings program. He was hired December 2018.


Quote Sources:

https://web.archive.org/web/20240408163612/https://spineblogger.blogspot.com/2011/05/whos-next.html?m=1
2016 10-k pg 13: https://www.sec.gov/Archives/edgar/data/1269026/000149315217010752/form10-k.htm
2017 results: https://ir.sintx.com/news-events/press-releases/detail/95/amedica-announces-results-of-independent-femoral-head-wear
https://web.archive.org/web/20240408152758/https://sintx.com/wp-content/uploads/2021/03/Investor-Call-Transcript-033021.pdf
https://www.researchgate.net/profile/Saurabh-Lal

========================================

Joe, you could have just posted this, but thank you for the link.

Rule 5815(d)(4)(A), entitled “Hearings Panel Monitor,” provides a Hearings Panel with
discretion to monitor a company for a period of up to one year after the date a company regains
compliance with a listing standard if it concludes that there is a likelihood that a company will
fail to maintain compliance with one or more listing standards during that period (including
requirements with which the company was not previously deficient). During this one-year
monitoring period, Staff will monitor the company, to confirm compliance with all listing
requirements. While Staff monitors all listed companies for compliance with the Exchange’s
listing standards, if Staff identifies a deficiency with any listing requirement for companies that
are being monitored under Rule 5815(d)(4)(A), staff may not provide the company with a cure or
compliance period, nor the opportunity to submit a plan to regain compliance with the
deficiency. Instead, Staff will issue a Delisting Determination for these companies.

As I already indicated, funds will want to keep SINT listed for liquidity purposes. Since they can only naked short so much, funds will need to keep SINT above 1 and have to look to profit more to the upside rather than downside.

https://www.sec.gov/files/rules/sro/nasdaq/2021/34-93789.pdf